Russia’s healthcare and medical market is undergoing a profound transformation. The pharmaceutical sector has reached record heights, the medical technology segment is expanding rapidly, and the government is pushing an ambitious program of import substitution to reduce dependence on foreign suppliers. Yet beneath the growth statistics lie deep structural challenges: a persistent workforce shortage, rising costs, and a critical need for innovation.
Pharmaceutical Market: Record Growth and Shifting Dynamics
The Russian pharmaceutical market reached 3.34 trillion rubles by the end of 2025, an increase of 17% year-on-year. This includes both government procurement and commercial pharmacy sales. The commercial drug market alone grew 13.1% to 1.85 trillion rubles, while over-the-counter products (parapharmaceuticals) expanded 17% to 464 billion rubles.
Government procurement emerged as the primary growth driver in 2025, rising 26% year-on-year. Analysts attribute this surge to expanded state guarantees in healthcare programs and increased allocations for high-cost disease treatments. The market is projected to exceed 3 trillion rubles in 2026, though growth is expected to slow to approximately 10.9% as the market adjusts to a higher base.
The Import Substitution Milestone
A landmark shift occurred in 2025: domestically produced drugs surpassed 50% of the pharmaceutical market for the first time, reaching a 50.3% share. In government procurement, Russian pharmaceutical companies increased their revenue by one-third.
However, the import substitution picture is nuanced. While domestic drugs dominate in volume terms, foreign drugs still command a significant share in value. In 2025, imported drugs accounted for a majority of government procurement spending, though this represents a decrease from 2024. Government institutions purchased millions of packages of imported innovative drugs in 2025, a significant increase in value from the previous year.
The Innovation Gap
Despite production growth, Russia faces a significant innovation challenge. Only a limited number of new clinical trial permissions were issued in 2025—significantly fewer than in previous years. The majority of these were for generics rather than innovative new drugs. Industry leaders have cited intellectual property risks as a major factor discouraging investment in clinical trials, noting that unresolved patent disputes create financial burdens for pharmaceutical companies.
Experts predict that the number of new innovative drugs entering the Russian market will continue to decline, as not all international pharmaceutical developments are being launched in Russia. In 2025 alone, Russia may miss access to many innovative drugs approved in the United States for socially significant diseases.
Long-term Investment
The government has approved plans to launch at least 11 new pharmaceutical production facilities by 2035 with total investment of 48 billion rubles. Investment allocation targets:
- 40% for full-cycle universal production facilities
- 25% for vaccine production
- 22% for oncology drugs
Two breakthrough projects were launched in 2025 with combined investment of 16 billion rubles.
Medical Devices: A Growing Market
The Russian medical devices market reached 876.6 billion rubles in 2025, a 3% increase from the previous year, with a five-year average annual growth rate of 5%. The top three segments by sales volume are:
- In-vitro diagnostics (laboratory analysis)
- General surgery and endoscopy
- Cardiovascular surgery and neurosurgery
Import Substitution in Medical Devices
Domestic medical device production increased its market share to 32% in 2025, up from 30% in 2024—a significant five-year rise. The rehabilitation and restorative medicine segment leads in localization at 74%, driven by Russian government corporation Rostec’s enterprises.
Rostec, which holds a portfolio of approximately 200 medical device types, invested 279 million rubles in medical projects in 2025 and plans to quadruple its market presence in the coming years, launching mass production of approximately 40 new types of equipment.
However, the high-tech medical equipment segment remains dominated by international brands, particularly in imaging, endoscopy, and intensive care. Foreign components, parts, and materials account for a significant share of Russian medical device production, and Russian manufacturers face challenges with equipment maintenance and repair due to limited domestic microelectronics capabilities.
Medical Technology Market
Russia’s medical technology market (medtech), including telemedicine, medical software, and device manufacturers, expanded by 21.4% in 2025, with combined revenue of the largest medtech companies reaching 60.6 billion rubles ($772 million).
Key medtech segments:
- Medical devices (cardiac and neurosurgery equipment, bionic prosthetics, aligners): fastest growth at 38.1%
- Research segment: expanded 22%
- Telemedicine: grew 17.6% to 21 billion rubles ($268 million), increasing market share to 35%
- Software development: grew 16.3% to 16.6 billion rubles ($211 million)
Major healthcare platforms remained market leaders with significant revenue growth year-on-year.
Rising Costs and Corporate Healthcare
Voluntary health insurance costs surged in 2025, outpacing official inflation. Average clinic prices rose 10-25% depending on facility level, compared to the official inflation rate. Medical services rose by an average of 11.94% nationwide between January 2025 and January 2026.
Key cost drivers include:
- Equipment and medical supplies inflation
- Personnel shortages driving wage increases
- Tax changes
Insurers reported DMS payouts increased significantly in 2025, while claims also rose. The corporate DMS market expanded notably, though the average cost of insuring one employee jumped significantly. Companies expect DMS costs to rise further in 2026.
Workforce Challenges
Personnel shortages remain critical. In late 2025, some regions faced pharmacy staff shortages of up to 30% due to low salaries, heavy workloads, and regulatory complexity. The healthcare sector faces a projected need to add hundreds of thousands of medical workers by 2032, prompting major reforms to medical education and residency programs.
Government Priorities for 2026
The Ministry of Health has set key objectives for 2026:
- Implementation of the national project for healthcare modernization
- Expansion of telemedicine technologies within the state guarantees program
- Remote monitoring for patients with hypertension or elevated blood sugar
- Expansion of high-tech medical care
President Putin noted that domestic medical equipment accounts for approximately 70% of supplies to healthcare facilities, and infant mortality fell to its lowest level in Russian history.
Outlook
The Russian medical market continues to expand, driven by government investment, import substitution, and rising demand for healthcare services. The pharmaceutical market is projected to reach 3.9 trillion rubles by 2027, while medtech is forecast to grow 15-17% in the first half of 2026.
However, significant challenges remain: innovation gaps, workforce shortages, rising costs, and persistent reliance on imported high-tech components and equipment. The government’s push for technological sovereignty in healthcare will require sustained investment in domestic production, research and development, and workforce training to close these gaps.
